clinical trials
-
How to interpret clinical trial results for Long COVID
With no proven treatments or cures, many people with Long COVID are turning to off-label medications, supplements, and medical devices to treat their symptoms. There are numerous options — and some of them even have clinical trials underway or are reporting results. But even if one study suggests a treatment might work, another might contradict…
-
Research updates, July 21
The dementia drug donepezil helped decrease fatigue in a subset of people with Long COVID, according to a study published in Frontiers in Pharmacology. In the complex study, which also included testing in mice, Japanese researchers found a majority of people with Long COVID in the cohort had reactivated human herpes virus 6 (HHV-6), which produced…
-
Experimental peptides are being advertised for Long COVID. But the evidence is trailing behind.
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.
-
Research updates, July 14
COVID-19 can cause long-term eye disorders, according to a cross sectional study in Nature Communications. Researchers in Sweden assessed 100 people with Long COVID and compared them to 32 people who had COVID-19 and “recovered.”
-
Research updates, July 7
An autopsy study found persistent SARS-CoV-2 virus in the hearts of some people who had died after having COVID-19. A part of the National Institute of Health’s RECOVER program, the researchers shared their unpublished results in a poster at a pathology conference this spring.
-
Research updates, June 30
A recent imaging study in Sage Journals identified metabolic dysfunction in the brains of people with Long COVID who experience PEM. The study assessed 40 people with the disease from a Long COVID clinic with an advanced imaging technique that can detect various cancers and neurologic conditions.
-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say.
-
Research updates, June 16
Two recent studies have added more evidence that the diabetes drug metformin can reduce the risk of Long COVID.
-
Research ethics boards need urgent training on Long COVID and myalgic encephalomyelitis
Last year, researchers in Ontario, Canada started recruiting participants for a Long COVID trial testing the feasibility of exercise and rehabilitation. Like many other studies of exercise, it doesn’t use validated measures for post-exertional malaise (PEM). But the Pursuing Reduction in Fatigue After COVID-19 via Exercise and Rehabilitation (PREFACER) study, run by researchers at Western…
-
Why are RECOVER’s first round of Long COVID clinical trials failing?
The U.S.’s flagship Long COVID research program has received over a billion dollars in funding and had years of input from people with the disease. But its first round of clinical trials are failing, at least in the results out so far.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance